Cathay Biotech Inc. (SHA: 688065)

Market Cap	30.23B
Revenue (ttm)	2.76B
Net Income (ttm)	397.82M
Shares Out	581.32M
EPS (ttm)	0.68
PE Ratio	76.43
Forward PE	n/a
Dividend	0.19 (0.35%)
Ex-Dividend Date	Jul 24, 2024

Volume	6,069,523
Open	53.71
Previous Close	53.53
Day's Range	51.82 - 55.50
52-Week Range	32.48 - 56.98
Beta	0.64
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 28, 2024

About Cathay Biotech

Cathay Biotech Inc., a bio-manufacturing technology company, researches, develops, produces, and sells bio-based materials in China and internationally. It offers biological long-chain diacids comprising sebacic acid and octadecanedioic acid; bio-based polyamides; and bio-based pentamethylene diamine. The products are used in various applications, including textiles, pharmaceuticals, perfumes, automobiles, electronic appliances, consumer goods, and other industries. It provides its products under the TERRYL and ECOPENT brands. Cathay Biotech In...

• Industry: Chemicals
• Sector: Materials
• Founded: 2000
• Employees: 1,803
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688065

Financial Performance

In 2023, Cathay Biotech's revenue was 2.11 billion, a decrease of -13.39% compared to the previous year's 2.44 billion. Earnings were 366.52 million, a decrease of -33.75%.